Sarah Cannon Research Institute (SCRI) is a research organization focusing on therapies for patients which include drugs that are in development. With corporate headquarters in Nashville, Tennessee, United States, it conducts community-based clinical trials in oncology, cardiology, gastroenterology, and other therapeutic areas. The current CEO is Dee Anna Smith. SCRI accrued more than 2,500 patients to cancer trials in 2009, including more than 500 to Phase I investigational studies. Non-oncology trials accounted for nearly 1,500 additional patients for a total of almost 4,000. More information...
According to PR-model, sarahcannon.com is ranked 514,348th in multilingual Wikipedia, in particular this website is ranked 287,043rd in English Wikipedia.
The website is placed before amcoz.com.au and after capitalwing.org in the BestRef global ranking of the most important sources of Wikipedia.
